2352-5126

JAAD Case Reports

Elsevier

View prefix report (10.1016)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 4915 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact4915 DOIs
2

Attach ORCID iDs across 4129 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact4129 DOIs
3

Deposit reference lists for 344 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact344 DOIs

DOIs for this ISSN

Showing the top 5 of 4915 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Morbilliform exanthem associated with COVID-19 (10.1016/j.jdcr.2020.04.015)
Abstract References ORCID
131.69 56
2 Coronavirus (COVID-19) infection–induced chilblains: A case… (10.1016/j.jdcr.2020.04.011)
Abstract ORCID
114.50 194
3 Introduction to reflectance confocal microscopy and its use… (10.1016/j.jdcr.2018.09.019)
Abstract ORCID
102.27 110
4 Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b… (10.1016/j.jdcr.2021.04.014)
Abstract ORCID
97.95 90
5 Immune-related sarcoidosis observed in combination ipilimuma… (10.1016/j.jdcr.2016.05.002)
Abstract ORCID
97.22 87
6 Pembrolizumab-associated sarcoidosis (10.1016/j.jdcr.2016.06.004)
Abstract ORCID
94.60 77
7 Oral angiotensin-converting enzyme inhibitors for treatment… (10.1016/j.jdcr.2021.02.018)
Abstract ORCID
93.17 72
8 Nivolumab-related cutaneous sarcoidosis in a patient with lu… (10.1016/j.jdcr.2017.02.015)
Abstract ORCID
92.87 71
9 Drug-induced alopecia after dupilumab therapy (10.1016/j.jdcr.2018.10.010)
Abstract ORCID
92.56 70
10 Alopecia areata after dupilumab for atopic dermatitis (10.1016/j.jdcr.2017.11.020)
Abstract ORCID
91.30 66
11 Development of bullous pemphigoid during nivolumab therapy (10.1016/j.jdcr.2016.05.009)
Abstract ORCID
90.98 65
12 Treatment of generalized deep morphea and eosinophilic fasci… (10.1016/j.jdcr.2017.12.003)
Abstract ORCID
90.98 65
13 Erythrodermic presentation of psoriasis in a patient treated… (10.1016/j.jdcr.2018.05.014)
Abstract ORCID
90.31 63
14 Tocilizumab for treatment of cutaneous and systemic manifest… (10.1016/j.jdcr.2022.02.022)
Abstract ORCID
90.31 63
15 Dupilumab facial redness: Positive effect of itraconazole (10.1016/j.jdcr.2019.07.020)
Abstract ORCID
87.02 54
16 “COVID arm”: A reaction to the Moderna vaccine (10.1016/j.jdcr.2021.02.014)
Abstract ORCID
86.62 53
17 Resolution of cutaneous sarcoidosis after Janus kinase inhib… (10.1016/j.jdcr.2019.02.006)
Abstract ORCID
86.21 52
18 The role of expanded series patch testing in identifying cau… (10.1016/j.jdcr.2018.08.027)
Abstract ORCID
85.38 50
19 Infliximab therapy for Netherton syndrome: A case report (10.1016/j.jdcr.2017.07.019)
Abstract ORCID
84.95 49
20 Tofacitinib shows benefit in conjunction with other therapie… (10.1016/j.jdcr.2019.10.010)
Abstract ORCID
84.95 49
21 Increasing evidence for omalizumab in the treatment of bullo… (10.1016/j.jdcr.2020.01.002)
Abstract ORCID
84.95 49
22 Hair regrowth in 2 patients with recalcitrant central centri… (10.1016/j.jdcr.2019.12.008)
Abstract ORCID
84.06 47
23 Insulin-derived amyloidosis: The insulin ball, amyloidoma (10.1016/j.jdcr.2020.02.011)
Abstract ORCID
84.06 47
24 A case of severe cutaneous adverse reaction following admini… (10.1016/j.jdcr.2021.05.010)
Abstract ORCID
84.06 47
25 Janus kinase inhibition in Down syndrome: 2 cases of therape… (10.1016/j.jdcr.2019.02.007)
Abstract ORCID
83.60 46
26 Acceleration of cutaneous T-cell lymphoma following dupiluma… (10.1016/j.jdcr.2020.12.010)
Abstract ORCID
83.60 46
27 Review of dupilumab-associated inflammatory arthritis: An ap… (10.1016/j.jdcr.2021.12.011)
Abstract ORCID
83.60 46
28 Toxic epidermal necrolysis (TEN) associated with the use of… (10.1016/j.jdcr.2017.09.028)
Abstract ORCID
83.14 45
29 Secukinumab and hidradenitis suppurativa: Friends or foes? (10.1016/j.jdcr.2018.12.002)
Abstract ORCID
83.14 45
30 Drug-induced hypersensitivity syndrome with myocardial invol… (10.1016/j.jdcr.2019.07.004)
Abstract ORCID
83.14 45
31 Dupilumab-induced phenotype switching from atopic dermatitis… (10.1016/j.jdcr.2020.01.012)
Abstract ORCID
83.14 45
32 Nivolumab-associated vitiligo-like depigmentation in a patie… (10.1016/j.jdcr.2016.10.008)
Abstract ORCID
82.66 44
33 Dupilumab for the treatment of severe atopic dermatitis in a… (10.1016/j.jdcr.2020.08.001)
Abstract ORCID
82.66 44
34 Alopecia areata in 2 patients treated with dupilumab: New on… (10.1016/j.jdcr.2019.03.019)
Abstract ORCID
81.67 42
35 Urticarial exanthem as early diagnostic clue for COVID-19 in… (10.1016/j.jdcr.2020.04.026)
Abstract ORCID
81.67 42
36 Alopecia areata after SARS-CoV-2 vaccination (10.1016/j.jdcr.2021.11.023)
Abstract ORCID
81.67 42
37 Severe cutaneous ulcerations secondary to xylazine (tranq):… (10.1016/j.jdcr.2023.04.016)
Abstract ORCID
81.67 42
38 Treatment-resistant dermatophytosis: A representative case h… (10.1016/j.jdcr.2020.05.025)
Abstract ORCID
81.16 41
39 Complete pathologic response of metastatic cutaneous squamou… (10.1016/j.jdcr.2017.06.005)
Abstract ORCID
80.64 40
40 Pityriasis rosea and pityriasis rosea-like eruptions: How to… (10.1016/j.jdcr.2018.04.002)
Abstract ORCID
80.10 39
41 Nivolumab-associated DRESS syndrome: A case report (10.1016/j.jdcr.2018.11.017)
Abstract ORCID
80.10 39
42 Sarcoid-like reaction in a patient recovering from coronavir… (10.1016/j.jdcr.2020.07.026)
Abstract ORCID
80.10 39
43 Acute generalized pustular psoriasis exacerbated by the COVI… (10.1016/j.jdcr.2021.08.035)
Abstract ORCID
80.10 39
44 Dual biologic therapy for recalcitrant psoriasis and psoriat… (10.1016/j.jdcr.2019.08.015)
Abstract ORCID
79.55 38
45 Recalcitrant prurigo nodularis treated successfully with dup… (10.1016/j.jdcr.2019.03.016)
Abstract ORCID
78.99 37
46 Talimogene laherparepvec for regionally advanced Merkel cell… (10.1016/j.jdcr.2017.02.003)
Abstract ORCID
78.41 36
47 Lifitegrast add-on treatment for dupilumab-induced ocular su… (10.1016/j.jdcr.2018.10.016)
Abstract ORCID
78.41 36
48 Incidental regression of an advanced basal cell carcinoma af… (10.1016/j.jdcr.2015.11.007)
Abstract ORCID
77.82 35
49 Talimogene laherparepvec induces durable response of regiona… (10.1016/j.jdcr.2019.06.034)
Abstract ORCID
77.82 35
50 Successful use of secukinumab in Netherton syndrome (10.1016/j.jdcr.2020.04.025)
Abstract ORCID
77.82 35